Press Releases

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

2003 Press Releases

Listed below are all of the QLT press releases available for the year you have selected.

December 9	QLT Announces 2003 Analyst & Investor Meeting and Webcast	PDF version
November 17	QLT Provides Update on American Academy of Ophthalmology Meeting	PDF version
November 6	QLT Files Form S-3 for its August 2003 Private Placement of Convertible Notes	PDF version
October 23	QLT Announces Q3 Results for 2003 and Updates Guidance	PDF version
October 20	QLT Announces Visudyne® Sales for the Third Quarter of 2003	PDF version
October 16	Visudyne® Approved in Japan for Treatment of Age-related Macular Degeneration (AMD)	PDF version
September 18	QLT Announces the Completion of Development Milestones in its Continued Efforts to Expand the Availability of Visudyne® in Wet AMD Market	PDF version
September 9	QLT Announces Favorable Vote from Medicare Panel to Support Visudyne® Therapy for Use in Occult Patients	PDF version
August 15	QLT Announces Closing of US $172.5 Million U.S. Private Convertible Senior Note Financing	PDF version
August 13	QLT Announces Exercise of Option to Acquire Additional US$22.5 Million Senior Convertible Notes	PDF version
August 12	Boyd Clarke Joins QLT's Board of Directors	PDF version
August 11	QLT Announces Terms of US $150 Million U.S. Private Convertible Senior Notes Offering	PDF version
August 11	QLT Announces TSX Approval of US $50 Million Share Repurchase Program	PDF version
August 11	QLT Announces Proposed US $50 Million Share Repurchase Program	PDF version
August 11	QLT Announces Proposed US $150 Million U.S. Private Convertible Senior Notes Offering	PDF version
July 23	QLT Announces Q2 Results for 2003 and Updates Guidance	PDF version
July 21	QLT Announces Visudyne® Sales for Second Quarter of 2003	PDF version
May 12	QLT Discontinues Tariquidar Phase III Non-Small Cell Lung Cancer Trials Following Planned Interim Analysis By The Independent Data Safety Monitoring Committee	PDF version
May 6	Visudyne® Receives Prestigious Award for Innovation in Eye Care	PDF version
May 6	New Clinical Data Confirm Role of Visudyne® (verteporfin) Therapy as Standard of Care in Choroidal Neovascularization (CNV) due to Age-Related Macular Degeneration	PDF version
April 24	QLT Announces Q1 Results for 2003 and Updates Guidance	PDF version
April 15	QLT Announces Visudyne® Sales for First Quarter of 2003	PDF version
March 28	QLT Announces Change in Reporting to U.S. GAAP and the U.S. Dollar from Canadian GAAP and the Canadian Dollar	PDF version
February 21	QLT Temporarily Suspends New Patient Accrual in Phase III Studies of Tariquidar Pending Planned Interim Analysis	PDF version
February 5	QLT Reports 2002 Fourth Quarter and Full-Year Earnings Per Share, Excluding Special Charges, of $0.16 and $0.47 and Provides Guidance for 2003	PDF version
January 23	QLT Announces Visudyne® Sales for Fourth Quarter and Fiscal Year 2002	PDF version
January 6	QLT to Participate in JP Morgan H&Q Healthcare Conference	PDF version

Visudyne® is a registered trademark of Novartis AG

Vancouver Web Design by Graphically Speaking